By: IPP Bureau
Last updated : August 18, 2026 4:19 pm
Rs. 76 crore deal lifts Piramal's stake from 33.33% to 74%, bringing vaccine and biologics CDMO capabilities fully in-house as part of its integrated service offering
Piramal Pharma Limited (PPL) has completed the acquisition of an additional 40.67% equity stake in Yapan Bio Private Limited, previously an associate company, converting it into a subsidiary.
The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as a follow-up to the company's earlier communication dated August 10, 2026, regarding the exercise of a call option to acquire the additional stake.
Piramal Pharma acquired 1,46,400 equity shares of Rs. 10 each in Yapan from its existing shareholders for an aggregate cash consideration of approximately Rs. 76 crore.
Following the transaction, the company's shareholding in Yapan increased from 33.33% to 74.00% of Yapan's equity share capital. As a result, Yapan has ceased to be an associate company and has become a subsidiary of Piramal Pharma, with the promoter/promoter group deemed to be indirectly interested in Yapan through the company's investment.
Yapan, incorporated on October 11, 2019, under the Companies Act, 2013, is a Contract Development and Manufacturing Organization (CDMO) specialising in process development, characterization, and Phase I/II GMP manufacturing services for vaccines and biologics.
The company's revenue from operations stood at Rs. 26.91 crore in FY2024, Rs. 54.40 crore in FY2025, and Rs. 26.34 crore in FY2026.
With this acquisition, Piramal Pharma will fully embed Yapan's advanced large molecule capabilities into its integrated service offering, enabling the company to develop and scale complex biologic therapies with greater efficiency.